JP2024500324A5 - - Google Patents
Info
- Publication number
- JP2024500324A5 JP2024500324A5 JP2023534386A JP2023534386A JP2024500324A5 JP 2024500324 A5 JP2024500324 A5 JP 2024500324A5 JP 2023534386 A JP2023534386 A JP 2023534386A JP 2023534386 A JP2023534386 A JP 2023534386A JP 2024500324 A5 JP2024500324 A5 JP 2024500324A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- use according
- pharmaceutical
- weeks
- dosage formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122117P | 2020-12-07 | 2020-12-07 | |
| US63/122,117 | 2020-12-07 | ||
| US202163211157P | 2021-06-16 | 2021-06-16 | |
| US63/211,157 | 2021-06-16 | ||
| US202163249468P | 2021-09-28 | 2021-09-28 | |
| US63/249,468 | 2021-09-28 | ||
| PCT/US2021/062286 WO2022125598A1 (en) | 2020-12-07 | 2021-12-07 | Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500324A JP2024500324A (ja) | 2024-01-09 |
| JP2024500324A5 true JP2024500324A5 (https=) | 2024-11-20 |
Family
ID=81972768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534386A Pending JP2024500324A (ja) | 2020-12-07 | 2021-12-07 | Ｇｌｐ－１ｒおよびｇｃｇｒ均衡アゴニストを使用した血糖および／または体重を低下させるための治療レジメンおよび方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134963A1 (https=) |
| EP (1) | EP4255564A4 (https=) |
| JP (1) | JP2024500324A (https=) |
| KR (1) | KR20230129425A (https=) |
| CA (1) | CA3201539A1 (https=) |
| IL (1) | IL303512A (https=) |
| MX (1) | MX2023006736A (https=) |
| WO (1) | WO2022125598A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240269238A1 (en) * | 2022-09-14 | 2024-08-15 | Spitfire Pharma Llc | Therapeutic Regimens and Methods for Reducing Body Weight in a Subject with Fatty Liver Disease using a GLP-1R and GCGR Agonist |
| JP2025537192A (ja) * | 2022-11-05 | 2025-11-14 | スピットファイア ファーマ エルエルシー | Ｇｌｐ－１ｒおよびｇｃｇｒアゴニストを使用した心血管リスク因子の処置のための治療レジメンおよび方法 |
| WO2025098416A1 (zh) * | 2023-11-06 | 2025-05-15 | 甘李药业股份有限公司 | 用于减肥的glp-1化合物 |
| WO2025193765A1 (en) * | 2024-03-12 | 2025-09-18 | Spitfire Pharma Llc | Therapeutic regimens and methods for reducing body weight and/or serum lipids using a glp-1r and gcgr agonist |
| CN118477048B (zh) * | 2024-05-24 | 2024-12-17 | 山东泰合医药科技有限公司 | 一种布瑞哌唑缓释微球及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
| PT3155017T (pt) * | 2014-05-28 | 2024-05-14 | Mederis Diabetes Llc | Farmacêuticos peptídicos melhorados para resistência à insulina |
| ES2983409T3 (es) * | 2016-03-10 | 2024-10-23 | Medimmune Ltd | Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| EP4506017A3 (en) * | 2018-01-03 | 2025-05-14 | Mederis Diabetes, LLC | Improved peptide pharmaceuticals for treatment of nash and other disorders |
| US12441776B2 (en) * | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
-
2021
- 2021-12-07 CA CA3201539A patent/CA3201539A1/en active Pending
- 2021-12-07 WO PCT/US2021/062286 patent/WO2022125598A1/en not_active Ceased
- 2021-12-07 KR KR1020237022812A patent/KR20230129425A/ko active Pending
- 2021-12-07 JP JP2023534386A patent/JP2024500324A/ja active Pending
- 2021-12-07 MX MX2023006736A patent/MX2023006736A/es unknown
- 2021-12-07 EP EP21904289.2A patent/EP4255564A4/en active Pending
- 2021-12-07 IL IL303512A patent/IL303512A/en unknown
-
2024
- 2024-11-11 US US18/943,449 patent/US20250134963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500324A5 (https=) | ||
| JP2006515351A5 (https=) | ||
| KR101174966B1 (ko) | 철이 발병에 관여하는 간질환의 치료 | |
| JP2022521233A5 (https=) | ||
| CN117355297A (zh) | 用于诱导褐色脂肪生成的方法和组合物 | |
| US20210401880A1 (en) | Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active Ingredient | |
| RS52867B (sr) | Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze | |
| JP7451413B2 (ja) | 肥満の治療および体重管理のためのｇｌｐ－１組成物 | |
| Wedemeyer et al. | 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31 | |
| JP2004526760A5 (https=) | ||
| JP2023510609A (ja) | Ｇｌｐ－１および／またはｇｌｐ－１類似体、ならびにインスリンおよび／またはインスリン類似体を含む併用療法 | |
| CN106822152B (zh) | 一种药物组合物及其应用 | |
| CN109999019B (zh) | 肉豆蔻脑酸甲酯在制备预防或治疗代谢综合征或改善机体能量代谢的产品中的应用 | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| JP2021169472A5 (https=) | ||
| JP7344422B2 (ja) | 糖尿病予防・治療用の医薬品組成物及びその用途 | |
| EP4090351B1 (en) | Dosing regimen of glp-1 | |
| US20240216384A1 (en) | Composition for preventing or treating metabolic diseases, containing tricyclo derivative compound | |
| US20250367215A1 (en) | Pharmaceutical combination comprising a cholane derivative and a statin or ursodesoxycholic acid | |
| JP5667565B2 (ja) | 閉経期、ホルモン変動および関節炎と関連する症状を治療するための組成物および方法 | |
| HK40094446A (zh) | Glp-1给药方案 | |
| JP5699030B2 (ja) | エタネルセプトを含む線維筋痛症の治療剤 | |
| KR20090103656A (ko) | 섬유근육통 치료제 | |
| US20200268820A1 (en) | Pharmaceutical composition and uses thereof | |
| CN120168610A (zh) | 一种白细胞介素-13在促进肌肉损伤后修复中的应用 |